| Bladder Cancer |
1 |
1 |
| Cancer |
0 |
0.95 |
| Prostate Cancer |
0 |
0.85 |
| Biologic Therapy |
0 |
0.69 |
| Antineoplastic Drug |
0 |
0.59 |
| Urothelial cancer |
0 |
0.56 |
| Genomic Medicine |
0 |
0.51 |
| Leukemia |
0 |
0.45 |
| Bladder |
0 |
0.35 |
| Chemotherapy |
0 |
0.3 |
| Europe |
0 |
0.25 |
| Generics |
0 |
0.2 |
| Prostate |
0 |
0.2 |
| Receptors |
0 |
0.2 |
| CAR-T |
0 |
0.17 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.17 |
| Tyrosine Kinase Inhibitor |
0 |
0.14 |
| Diffuse Large B-Cell Lymphoma |
0 |
0.13 |
| B-Cell Lymphoma |
0 |
0.11 |
| Follicular Lymphoma |
0 |
0.11 |
| Child |
0 |
0.1 |
| Lymphoma |
0 |
0.1 |
| Refractory |
0 |
0.1 |
| Chronic Myeloid Leukemia |
0 |
0.07 |